Argeris Karabelas, William Haseltime, Laura D Andrea Tyson | GenomeWeb

Argeris Karabelas will become the new chairman of the board of directors of Human Genome Sciences next month, replacing William Haseltime after his retirement, the company said on Monday. Karabelas is a partner of investment firm Care Capital and has been a director of Human Genome Sciences since 2002. He holds a PhD in pharmacokinetics from the Massachusetts College of Pharmacy. In addition, Human Genome Sciences has promoted Craig Rosen to president and chief operating officer, from president for research and development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.